Comprehensive Pharmacovigilance Analysis of Lebrikizumab: A Real-World Safety Assessment Based on the FDA Adverse Event Reporting System (FAERS) Database

Key Points

• The aim is to assess the safety profile of lebrikizumab using real-world data from the FAERS database.
• Conducted a pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database.
• Focused on analyzing reported adverse events associated with lebrikizumab.
• Evaluated safety data to determine long-term usability in clinical settings.
• Lebrikizumab demonstrates a favorable safety profile.
• Adverse event reports indicate the safety of lebrikizumab is manageable.
• Supports the use of lebrikizumab for long-term clinical practice.